-
COPD: Could there be a GLP-1 for that?
While real-world data are promising, experts Dinah Foer, MD, and William B. Feldman, MD, say more randomized controlled trials are needed to confirm whether antihyperglycemic medications can improve respiratory outcomes in patients with comorbid type 2 diabetes and COPD.
Recent News
-
Incorporating climate-related events into clinical practice
Review six steps a pulmonary clinician can take prior to a climate-related event to prepare for a potential disaster scenario and mitigate patient risk.
-
Improving compliance in NIV for COPD
High-intensity NIV is vital for patients with COPD with hypercapnic respiratory failure, and success often depends on overcoming patient intolerance.
-
Respiratory care: A glass half full?
The respiratory therapist workforce has been dwindling at a time when demand has been skyrocketing. But good news is on the horizon.
-
Parkinson’s drug shows promise as treatment for nicotine addiction in mouse model
Tobacco cessation expert, Carolyn Dresler, MD, MPA, said new evidence of cross talk between different types of acetylcholinergic receptors could be an important step for future research to determine if, and at what doses, these results could be replicated in humans.
-
Early treatment with CPAP may reduce dementia risk for patients with OSA
Sreelatha Naik, MD, FCCP, said the apparent benefit of CPAP therapy is not a surprise; however, more studies are needed to determine if treating sleep apnea can truly mitigate the higher risk of dementia.
-
Corticosteroid benefits unclear for acute ILD exacerbations
Erin Meier, MD, and Rachana Krishna, MBBS, MSCR, discuss the clinical implications of a recent meta-analysis, which suggests steroids may not help all patients with interstitial lung disease (ILD) who experience a flare.